Nymox Pharmaceutical Corporation (NYMX) shares are up nearly 31% to $1.64 in early trading. The move comes on a big volume too with the issue currently trading more than 7 million shares, compared to the average volume of 499K shares. Not seeing any news or rumors to account for the move.
Nymox Pharmaceutical is a Saint-Laurent, Canada-based biopharmaceutical firm focusing in the research and development of products for the aging population. Its stock has a median consensus analyst price target of $10, and a 52-week trading range of $0.33 to $5.76. The T-12 profit margin at Nymox is (171.58%). NYMX revenue for the same period is $3.16 million.
Nymox Pharmaceutical has market cap of $60.78 million.